The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) during the high-risk 90-day period following a heart attack KING OF PRUSSIA, Pa., Nov. 5, 2020 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced that the study design manuscript for its landmark AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes II) has been […]
Coronary/Structural Heart
MyoKardia Announces Awardees of the Second Annual MyoSeeds™ Research Grants Program
BRISBANE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant Program, who have been selected to receive $250,000 each in support of original, independent research in the biology and underlying mechanisms of cardiomyopathies. The MyoSeeds Program was founded […]
Saillant Therapeutics Reports Proof of Concept of its Treatment in Heart Failure showing Functional Reversal and Myocardial Rejuvenation
NIJMEGEN, Netherlands, Nov. 4, 2020 /PRNewswire/ — Saillant Therapeutics, an innovative preclinical stage biotechnology company developing promising small molecule-based therapies, today announced that it has obtained Proof of Concept for its lead compound (ST02) indicated for the treatment of heart failure. The compound was tested in a well-established preclinical heart failure model in which […]
Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)
CARLSBAD, Calif. and BOSTON, Nov. 3, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer Inc. (NYSE: PFE) has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in statin-treated patients with elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs). The study, Targeting ANGPTL3 with an antisense oligonucleotide in adults with dyslipidemia (TRANSLATE-TIMI […]
Abbott Wins Prestigious Prix Galien USA Award for First-of-its-Kind MitraClip™ Device
— Considered as the industry’s equivalent of the Nobel Prize in biopharmaceutical and medical technology research, Prix Galien USA honored MitraClip as the Best Medical Technology for 2020 — The groundbreaking MitraClip therapy has positively impacted the lives of more than 100,000 people globally living with mitral regurgitation, or a […]
Regeneron Once Again Earns #1 Ranking in Science Magazine’s Top Biopharma Companies to Work For
TARRYTOWN, N.Y., Oct. 29, 2020 /PRNewswire/ — Regeneron has been consistently ranked #1 or 2 Top Employer for past 10 years Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the company was once again ranked as the top company to work for by Science magazine in its annual Top Employers Survey of the global biotech and […]
HeartFlow Applauds Healthcare Stakeholders’ Push for Change in How Coronary Artery Disease is First Diagnosed
Use of coronary CTA instead of stress tests alone results in increased early initiation of preventative therapy and 41% reduction in cardiac death and myocardial infarction1 Publication in the Journal of the American College of Cardiology advocates coronary CTA to detect atherosclerosis and coronary artery blockages versus invasive imaging or […]
CHF Solutions Announces First Commercial Shipments of Aquadex Systems to Brazil, following Regulatory Approval
EDEN PRAIRIE, Minn., Oct. 29, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced it has shipped the first commercial orders of its Aquadex SmartFlow™ system to Brazil, following approval from the Brazilian Health […]
New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at American Heart Association’s Virtual Scientific Sessions 2020
Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Eight Presentations, Including REDUCE-IT® CABG (Coronary Artery Bypass Graft) Results and Additional Mechanism of Action Insights DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that new scientific findings that add […]
DiA Granted FDA Clearance for its Cardiac Ultrasound AI Auto Views Selection
This 7th FDA clearance further solidifies DiA’s leadership in the ultrasound AI space. BE’ER SHEVA, Israel, Oct. 29, 2020 /PRNewswire/ — DiA Imaging Analysis announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the commercial use of LVivo Seamless for automatic view selection. LVivo Seamless algorithms automatically […]



